Prostate Cancer

Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. June 24, 2022

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. June 24, 2022

The potential of hyperpolarised 13C-MRI to target glycolytic tumour core in prostate cancer. June 24, 2022

eHealth-Based Interventions for Older Patients with Prostate Cancer: A Quick Review of the Literature. June 24, 2022

The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response. June 24, 2022

US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. June 24, 2022

Factors Associated with Decision Aid Use in Localized Prostate Cancer. June 23, 2022

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. June 23, 2022

Practicalities, challenges and solutions to delivering a national organisational survey of cancer service and processes: lessons from the National Prostate Cancer Audit. June 23, 2022

Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: A Comparative Study. June 23, 2022

Expanding the Secondary Use of Prostate Cancer Real World Data: Automated Classifiers for Clinical and Pathological Stage. June 23, 2022

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. June 23, 2022

MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. June 22, 2022

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. June 22, 2022

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer. June 22, 2022

PROpel Phase III trial positive results of LYNPARZA® (olaparib) plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence June 21, 2022

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer June 21, 2022

Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer June 21, 2022

Blood-Based Liquid Biopsies for Prostate Cancer: Clinical Opportunities and Challenges June 21, 2022

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial June 21, 2022

Page 1 of 1230

email news signup